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Abstract:  We  examined  the  effects  of  oral  glucosamine  hydrochloride  (GlcN), 
N-acetyl-D-glucosamine (GlcNAc) and D-glucose (Glc) administration on plasma total free 
amino acid (PFAA)  concentrations in dogs. The PFAA concentrations increased in the 
control  group  and  the  GlcNAc  group  at  one  hour  after  feeding,  and  each  amino  acid 
concentration increased. On the other hand, in the GlcN group and the Glc group PFAA 
concentrations decreased at one hour after feeding. A significant decrease in amino acid 
concentration was observed for glutamate,  glycine and alanine. Our results suggest the 
existence of differences in PFAA dynamics after oral administration of GlcN and GlcNAc 
in dogs. 
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1. Introduction  
Glucosamine  hydrochloride  (GlcN)  and  N-acetyl-D-glucosamine  (GlcNAc)  are  components  of 
glycosaminoglycan now widely used as dietary supplements [1]. Moreover, GlcN is useful for the 
treatment of joint diseases both in humans and in veterinary medicine, including dogs and horses [2,3]. 
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The bioavailability of GlcN has been reported as 26% in humans [4], 19% in rats [5], 12% in dogs [6], 
and 2–6.1% in horses [7–9]. These results suggest the presence of a species-specific difference in GlcN 
absorption and metabolism. Different biological activities between GlcN and GlcNAc have also been 
demonstrated in vitro. For example, differences in GlcN and GlcNAc uptake and their subsequent 
effects on glucose transport, glucose transporter (GLUT) expression, and sulfated glycosaminoglycans 
(sGAG) and hyaluronan synthesis have been reported [10].  
In an experimental rabbit model of cartilage injury, oral administration of GlcN or GlcNAc led to 
regeneration of both glycosaminoglycan and proteoglycan [11,12]. GlcN has the potential to exert 
chondroprotective action on an experimentally induced osteoarthritis by inhibiting type II collagen 
degradation  and  enhancing  type  II  collagen  synthesis  in  the  articular  cartilage  [13].  These  results 
suggested  that  synthesis  of  type  II  collagen  and  proteoglycan  core  protein  as  well  as 
glycosaminoglycan occurs upon GlcN and GlcNAc supplementation. However, no reports to date have 
investigated the relationship between oral administration of amino monosaccharide and amino acid 
synthesis. 
The aim of this study was to examine the effects of oral GlcN and GlcNAc administration on 
plasma free amino acid (PFAA) concentrations. Using dogs, we investigated (PFAA) dynamics after 
oral administration of GlcN, GlcNAc, or glucose (Glc), which are the sources of glycosaminoglycan 
and proteoglycan in the body.  
2. Results and Discussion  
Amino acids measured in this study are shown in Table 1. The PFAA concentrations increased in 
the control dogs and the GlcNAc treated dogs whereas those from the GlcN- or the Glc-treated dogs 
significantly decreased after one hour (Figure 1). The levels of Glu, Gly, and Ala concentrations were 
significantly lower than observed fort he GlcNAc-treated dogs (Table 2). 
Table 1. Amino acids measured in this study. 
Essential amino acids (EAA)  Nonessential amino acids (NEAA) 
Threonine (Thr)  Asparate (Asp) 
Valine (Val)  Serine (Ser) 
Methionine (Met)  Asparagine (Asn) 
Isoleucine (Ile)  Glutamate (Glu) 
Leucine (Leu)  Glutamine (Gln) 
Phenylalanine (Phe)  Glycine (Gly) 
Lysine (Lys)  Alanine (Ala) 
Histidine (His)  Tyrosine (Tyr) 
Tryptophan (Trp)   Proline (Pro) 
Arginine (Arg)  Citrulline (Cit) 
  Ornithine (Orn) 
  Hydroxyproline (Hypro) 
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Figure 1. Changes in plasma total free amino acid (PFAA) concentration in dogs after each 
saccharide  (GlcN,  GlcNAc,  and  Glc)  administration.  Plasma  total  free  amino  acid 
concentration pre-administration was considered as 100%. *: p < 0.05, compared to the 
level  of  the  control  at  each  hour.  Data  represent  the  mean  ±   SE  of  three  dogs  in  
each group. 
 
After administration of GlcNAc, no remarkable change was observed in either PFAA concentration 
or each amino acid level compared to the control.  
Table 2. Significant changes in serum amino acid concentrations at 1 h after administration 
of each saccharide (GlcN, GlcNAc, and Glc) to dogs. 
  Control  GlcN  GlcNAc  Glc 
Glu  128.3 ±  6.4  98.6 ±  9.0*  184.0 ±  20.7  103.6 ±  10.1* 
Gly  126.8 ±  12.3  95.3 ±  5.8*  145.0 ±  6.1  100.9 ±  2.9* 
Ala  135.3 ±  21.9  82.8 ±  4.1*  148.3 ±  4.1  85.4 ±  5.6* 
Each  plasma  free  amino  acid  concentration  pre-administration  was  considered  as  100%. 
*: p < 0.05, compared to the levels of the GlcNAc or the control at 1 h after administration. Data 
represent the mean ±  SE of three dogs in each group. Control dogs were fed only dog food, and the 
other dogs were fed dog food supplemented with each saccharide. 
In a healthy human report, postprandial PFAA concentrations were raised compared to those before 
a meal [14]. Following feeding, PFAA increased in the control dogs and the GlcNAc-treated dogs. 
However, PFAA decreased compared to the control group after administration of GlcN or Glc. In an in 
vitro  study  using  mesenchymal  stem  cells,  treatment  with  100  μM  or  1,000  μM  GlcN  increased 
expression of aggrecan and type II collagen. Moreover, 100 μM GlcN treatment led to increased sGAG 
content [15]. In humans, plasma GlcN concentration reached 150–300 μM after oral administration of Mar. Drugs 2011, 9                                                  
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20 mg/kg GlcN [16]. In dogs, plasma GlcN concentration was reported to reach 50 μM after oral 
administration of 125 mg/kg GlcN [6], and reached 100 μM after oral administration of 300 mg/kg 
GlcN  (Figure  2).  Although  the  maximum  plasma  GlcN  concentration  achieved  after  oral 
administration of 500 mg/kg GlcN has not been reported, a previous study indicated that it exceeds  
100  μM.  These  findings  suggested  that  high  levels  of  GlcN  were  provided  to  the  tissue  by  the 
circulatory  system  in  dogs.  Naito  K  et  al.  described  that  GlcN  has  the  potential  to  exert  a 
chondroprotective action on an experimentally induced OA by inhibiting type II collagen degradation 
and enhancing type II collagen synthesis in the articular cartilage [13]. Therefore, proteoglycan and 
type II collagen were likely to be synthesized actively in cartilage. Gly, Ala and Glu are the main 
components of type II collagen [17], and the levels of these amino acids became lower than those of 
the control and GlcNAc-treated dogs after administration of GlcN or Glc. These results suggest that 
GlcN or Glc stimulated proteoglycan and type II collagen synthesis in the dogs.  
No change in total or individual amino acid concentrations was observed after administration of 
GlcNAc compared to the control group. The maximum concentration of GlcNAc in dogs reached 
about 20 μM after 300 mg/kg GlcNAc administration (Figure 2). Therefore, absorption of GlcNAc by 
the canine gut may be inferior to that of GlcN. However, the mechanisms of GlcNAc absorption are 
unclear; further investigation into the absorption and metabolism of GlcNAc is necessary. 
In  our  pilot  study  using  a  horse,  plasma  ammonia  concentration  increased  from  2  h  after 
administration of GlcN. The level of PFAA increased compared to pre-administration levels (data not 
shown).  The  presence  of  a  species-specific  difference  in  GlcN  absorption  and  metabolism  was 
suggested [4–9].  
We  did  not  directly  confirm  type  Ⅱ  collagen  and  proteoglycan  synthesis  in  dogs  after 
administration of GlcN. However, oral administration of GlcN induced obvious functional recovery in 
various kinds of canine orthopedic diseases [2]. To confirm these phenomena occur in dogs is required 
to understand the mechanism of GlcN in dog joint diseases. 
Figure 2. Changes in plasma GlcN or GlcNAc concentration after oral GlcN or GlcNAc 
administration. All data indicate mean  S.D. *: P < 0.05 compared to GlcN group. 
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3. Experimental Section  
3.1. Materials 
Glucosamine hydrochloride (GlcN) was supplied by Koyo Chemical Co., Ltd., (Tokyo, Japan).  
N-Acetyl-D-glucosamine  (GlcNAc)  was  supplied  by  Yaizu  SuisannKagaku  Industry  Co.,  Ltd., 
(Shizuoka,  Japan).  D-Glucose  (Glc),  molecular  weight  180.16,  was  purchased  from  Wako  Pure 
Chemical (Osaka, Japan). 
3.2. Animals 
Three healthy beagle dogs, mean age of 4 years (range 2–6 years) and mean body weight 9 kg 
(range 7–12 kg). The use of these animals and the procedures they underwent were approved by the 
Animal Research Committee of Tottori University. 
3.3. Administration and Blood Sampling 
Dogs  were  separated  into  the  following  groups  (n  =  3  for  each  group):  usual  dog  food  
(Hill’s-Colgate (Japan) Ltd, Science Diet, Tokyo, Japan) (Control), usual dog food plus GlcN, usual 
dog food plus GlcNAc, and usual dog food plus Glc. Each saccharide dissolved in water was orally 
administered at approximately 500 mg/kg to dog. Dog’s blood was collected (0 h) in the morning 
before being fed, then 35 kcal/kg body weight dog food with each saccharide dissolved in 10 mL water 
(500 mg/kg body weight, single dose) was fed (10 mL water for control group) (first feeding). After 
blood collection at 1, 2, 4, and 6 h, all the dogs were fed with 35 kcal/kg dog food without saccharide 
(second feeding), and the blood was collected 18 h after second feeding. 
Blood  was  collected  from  the  jugular  vein  using  heparin  as  an  anti-coagulant.  The  blood  was 
centrifuged at 3,000 rpm for 10 min, and the plasma was then separated promptly and frozen at −80 ºC  
until measurement of PFAA concentrations.  
3.4. Measurement of PFAA Concentrations 
Plasma samples were mixed with equal volumes of 3% (w/w) sulfosalicylic acid, and left to stand at 
4 °C  for 1 h. Samples were then centrifuged (4 ° C, 15 min, 1,500 rpm), and precipitated protein was 
removed.  The  amino  acid  concentrations  were  measured  by  an  automatic  amino  acid  analyzer  
(JLC-500/V2, AminoTac; JEOL, Tokyo, Japan). The amino acids measured are listed in Table 1.  
3.5. Measurement of Plasma GlcN and GlcNAc Concentrations 
GlcN or GlcNAc dissolved in water was orally administered at approximately 300 mg/kg to dogs  
(n = 3 in each group). Blood samples were collected before administration and 0.5, 1, 2, 4, and 24 h 
after administration. Blood was collected from the jugular vein using heparin as an anti-coagulant. The 
blood was centrifuged at 3,000 rpm for 10 minutes, and the plasma was then separated promptly. 
Plasma samples were mixed with four equal volumes of ethanol and centrifuged, and precipitated 
protein was removed. These samples were treated using a p-ethyl 4-aminobenzoate carbohydrate chain 
labeling  kit  (Seikagaku  Kogyo,  Tokyo,  Japan).  Samples  were  analyzed  quantitatively  using  high Mar. Drugs 2011, 9                                                  
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performance  liquid  chromatography  fitted  with  a  reversed-phase  column  (Honenpak  C18,  
75 mm ×  4.6 mm I.D.) and fluorometer (Ex. 305 nm, Em. 360 nm).  
3.6. Statistical Analysis 
Each amino acid concentration, total amino acid concentration, essential amino acid concentrations 
and nonessential amino acid concentrations were used for the evaluation. In dogs, total amino acid 
concentrations were expressed as the percentage of pre-administration values. Student’s t-tests were 
used  to  assess  differences  at  each  time  point.  A  probability  of  5%  or  less  was  considered  
statistically significant. 
4. Conclusions  
In this study, we investigated differences in plasma amino acid dynamics after oral administration 
of GlcN, GlcNAc and Glc to dogs. Our results indicate that oral administration in dogs of GlcN or Glu, 
but not GlcNAc, lowers the levels of some free amino acids in plasma. This result indicates that further 
work  is  warranted  to  determine  the  significance  of  this  finding  for  the  impact  of  these  dietary 
supplements on amino acid metabolism and utilization. 
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